Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Neurological Medicine
Volume 2014, Article ID 786342, 4 pages
http://dx.doi.org/10.1155/2014/786342
Case Report

Diagnosis of Exclusion: A Case Report of Probable Glatiramer Acetate-Induced Eosinophilic Myocarditis

1Department of Pharmacy, Spectrum Health, 100 Michigan Street NE, MC 001, Grand Rapids, MI 49503, USA
2Internal Medicine, Spectrum Health, Grand Rapids, MI 49503, USA
3Pulmonary Critical Care, Spectrum Health Medical Group, Grand Rapids, MI 49503, USA

Received 30 April 2014; Accepted 16 June 2014; Published 3 July 2014

Academic Editor: Samuel T. Gontkovsky

Copyright © 2014 Christopher J. Michaud et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. B. C. Kieseier and O. Stüve, “A critical appraisal of treatment decisions in multiple sclerosis-old versus new,” Nature Reviews Neurology, vol. 7, no. 5, pp. 255–262, 2011. View at Publisher · View at Google Scholar · View at Scopus
  2. G. L. Plosker, “Interferon-β-1b: a review of its use in multiple sclerosis,” CNS Drugs, vol. 25, no. 1, pp. 67–88, 2011. View at Publisher · View at Google Scholar · View at Scopus
  3. J. A. Cohen, F. Barkhof, G. Comi et al., “Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis,” The New England Journal of Medicine, vol. 362, no. 5, pp. 402–415, 2010. View at Publisher · View at Google Scholar · View at Scopus
  4. Copaxone [package insert], TEVA Neuroscience, Inc., Kansas City, Mo, USA.
  5. O. Khan, P. Rieckmann, A. Boyko, K. Selmaj, and R. Zivadinov, “Three times weekly glatiramer acetate in relapsing-remitting multiple sclerosis,” Annals of Neurology, vol. 73, no. 6, pp. 705–713, 2013. View at Publisher · View at Google Scholar · View at Scopus
  6. Y. Ramot, M. Rosenstock, E. Klinger, D. Bursztyn, A. Nyska, and D. M. Shinar, “Comparative long-term preclinical safety evaluation of two glatiramoid compounds (glatiramer Acetate, Copaxone, and TV-5010, protiramer) in rats and monkeys,” Toxicologic Pathology, vol. 40, no. 1, pp. 40–54, 2012. View at Publisher · View at Google Scholar · View at Scopus
  7. J. S. Wolinsky, P. A. Narayana, P. O'Connor et al., “Glatiramer acetate in primary progressive multiple sclerosis: results of a multinational, multicenter, double-blind, placebo-controlled trial,” Annals of Neurology, vol. 61, no. 1, pp. 14–24, 2007. View at Publisher · View at Google Scholar · View at Scopus
  8. G. Comi, M. Filippi, and J. S. Wolinsky, “European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis,” Annals of Neurology, vol. 49, no. 3, pp. 290–297, 2001. View at Publisher · View at Google Scholar · View at Scopus
  9. M. B. Bornstein, A. Miller, S. Slagle et al., “A pilot trial of cop 1 in exacerbating-remitting multiple sclerosis,” The New England Journal of Medicine, vol. 317, no. 7, pp. 408–414, 1987. View at Publisher · View at Google Scholar · View at Scopus
  10. C. J. M. Sindic, P. Seeldrayers, L. Vande Gaer et al., “Long-term follow up of glatiramer acetate compassionate use in Belgium,” Acta Neurologica Belgica, vol. 105, no. 2, pp. 81–85, 2005. View at Google Scholar · View at Scopus
  11. K. P. Johnson, B. R. Brooks, J. A. Cohen et al., “Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability,” Neurology, vol. 50, no. 3, pp. 701–708, 1998. View at Publisher · View at Google Scholar · View at Scopus
  12. L. La Mantia, L. M. Munari, and R. Lovati, “Glatiramer acetate for multiple sclerosis,” Cochrane Database of Systematic Reviews, vol. 12, no. 5, pp. 1–61, 2010. View at Publisher · View at Google Scholar · View at Scopus
  13. P. Cacoub, P. Musette, V. Descamps et al., “The DRESS syndrome: a literature review,” The American Journal of Medicine, vol. 124, no. 7, pp. 588–597, 2011. View at Publisher · View at Google Scholar · View at Scopus
  14. J. A. Cohen, M. Rovaris, A. D. Goodman, D. Ladkani, D. Wynn, and M. Filippi, “Randomized, double-blind, dose-comparison study of glatiramer acetate in relapsing-remitting MS,” Neurology, vol. 68, no. 12, pp. 939–944, 2007. View at Publisher · View at Google Scholar · View at Scopus
  15. “From FDA Reports: Copaxone and Eosinophilia,” http://www.ehealthme.com/ds/copaxone/eosinophilia.
  16. S. A. Walsh and D. Creamer, “Drug reaction with eosinophilia and systemic symptoms (DRESS): a clinical update and review of current thinking,” Clinical and Experimental Dermatology, vol. 36, no. 1, pp. 6–11, 2011. View at Publisher · View at Google Scholar · View at Scopus
  17. J. R. Sullivan and N. H. Shear, “The drug hypersensitivity syndrome: what is the pathogenesis?” Archives of Dermatology, vol. 137, no. 3, pp. 357–364, 2001. View at Google Scholar · View at Scopus
  18. C. A. Naranjo, U. Busto, and E. M. Sellers, “A method for estimating the probability of adverse drug reactions,” Clinical Pharmacology and Therapeutics, vol. 30, no. 2, pp. 239–245, 1981. View at Publisher · View at Google Scholar · View at Scopus